In survival analysis, pairwise comparisons showed significant differences in the metastasis-free survival (for the TCGA dataset: P = 0.002, Fig. 1d; for the Taylor dataset: P = 0.026, Fig. 1e) between prostate cancer patients with high SLC6A1and low SLC6A1 expression. This evidence concerns the gene SLC6A1 and Familial prostate cancer.